Eudragit® RS100 microspheres of two chalcones were prepared by solvent evaporation technique. A simple and rapid high-performance liquid chromatography (HPLC) method was developed and validated to determine the encapsulation efficiency, drug loading and release profiles of these chalcones in a microparticulate system. The mean EE values for the two chalcones-loaded microparticles were 98.8 ± 1.3% and 99.5 ± 0.9%. Scanning electron microscope (SEM) studies showed that one chalcone-loaded microspheres are spherical and smooth appearance whereas the other chalcone-loaded microspheres showed irregular particles and a rough surface. The analysis of the second chalcone by thermogravimetric analysis (TGA) showed a higher thermal stability compared to the first chalcone. Drug release profiles were determined at pH 7.4 phosphate buffered saline (100 mmol L-1) with sodium lauryl sulfate (0.5%). The systems prepared with Eudragit® showed 78 and 95% of the two chalcones were released after 24 hours. The experimental results indicated that the prepared polymeric microspheres may be useful for potential applications.

Gene therapy is a promising tool for the treatment of ocular diseases. Nevertheless, there are some import limitations, especially related to the ocular route and the characteristics of nucleic acids that must be overcome to ensure the success of the therapy. In this context, nanotechnology-based carriers such as nanoemulsions, nanoparticles, dendrimers and liposomes have risen as a promising vehicle for the protection of genetic material for vectoring the target cells. The success of such approach is closely related to the judicious selection of the biomaterial, where chemical structure and intermolecular interactions play a major role. So, this manuscript reviews some of the most important biomaterials, lipid and polymeric origin, employed in the manufacture of nanotechnologic carriers for ocular gene therapy involving interfering RNA (siRNA), antisense oligonucleotide (AS-ON) and plasmid DNA (pDNA).

Cecropia glaziovi Snethl., Urticaceae, is commonly used in South America and is one of the species included in the Brazilian Medicinal Plants Research Program. Pharmacological studies have led to reports of the potential of C. glaziovi as a hypotensive, antiasthmatic and anxiolytic agent. The strict requirements regarding the quality, safety and effectiveness of phytopharmaceutical products represent an enormous challenge in the search for products with a high level of uniformity, reproducibility and stability. The incorporation of dry extracts into multiparticulate dosage forms, such as pellets produced by extrusion/spheronization technology, is a suitable alternative to overcome the lack of technological properties of dry extracts, since they are associated with low flowability and high hygroscopicity. In this study, an optimized dry extract (ODE) of C. glaziovi was incorporated into pellets seeking to decrease the moisture sorption and increase the stability, safety and percentage of the extract in the final product. Pellets containing around 50% of ODE were considered the most technologically viable, offering a narrow particle size distribution, significant improvement in the flowability and compressibility properties, and decrease in the moisture compared with the ODE. In conclusion, pellets containing a high dose of the C. glaviovi extract were successfully prepared, achieving degrees of quality, physical stability and feasibility compatible with the desirable characteristics of a phytopharmaceutical.